UBS Group
IMCR icon

UBS Group’s Immunocore IMCR Stock Holding History

UBS Group’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,200
Closed -$208K – 9230
2023
Q1 		$208K Hold
4,200
– – ﹤0.01% 5361
2022
Q4 		$240K Hold
4,200
– – ﹤0.01% 5308
2022
Q3 		$197K Buy
+4,200
New +$200K ﹤0.01% 5094

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

UBS Group's IMCR Position: Q2 2026 in Review

UBS Group reduced its Immunocore (IMCR) stake by 69% in Q2 2026, selling an estimated $859K and leaving 13,101 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #6358.

UBS Group first reported a position in IMCR in Q1 2021 and has held it in 22 quarters since. The position peaked at $5.23M in Q1 2025. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • UBS Group held 13,101 shares of Immunocore worth $416K as of Q2 2026.
  • UBS Group sold 29,033 Immunocore shares in Q2 2026, an estimated $859K.
  • Immunocore made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6358 holding.
  • UBS Group first reported a position in Immunocore in Q1 2021 and has held it in 22 quarters since.
  • UBS Group's Immunocore position peaked at $5.23M in Q1 2025.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.